Role and Timing of Radiotherapy in High-Risk Endometrial Cancer

Basit Öğe Kaydı
dc.contributor.authorYavas, Guler
dc.date.accessioned2020-03-26T19:42:32Z
dc.date.available2020-03-26T19:42:32Z
dc.date.issued2017
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractEndometrial cancer is the most common gynecological tumor in developed countries, and its incidence is increasing because of an increased prevalence of obesity and an aging population. Although most patients present with early-stage low-risk disease, a rise in the incidence is attributed to an increasing number of high-risk cases at the time of diagnosis. Despite optimal surgical treatment, the prognosis of high-risk endometrial cancer (HREC) is poor because of increased risk of local and distant recurrences and therefore, adjuvant treatment should be considered. Although the definition of high-risk patients varies between cooperative groups, the recent endometrial consensus conference defined high-risk patients as follows: (1) stage I endometrioid, grade 3, >= 50% myometrial invasion; (2) stage II disease; (3) stage III endometrioid, no residual disease; and (4) non-endometrioid histology. The optimal adjuvant treatment is controversial; however, multimodality treatment is recommended. External radiotherapy seems to be reasonable in HREC and is indicated to improve pelvic relapses. The use of adjuvant chemotherapy is also reasonable for preventing or delaying distant metastases. There is limited evidence for the benefit of vaginal cuff brachytherapy after external radiotherapy. Optimal sequence of radiation and chemotherapy is not well defined; however, concurrent chemoradiotherapy plus adjuvant chemotherapy, "sandwich" approach, and providing radiotherapy after the completion of chemotherapy may be reasonable. The role of adjuvant radiotherapy with systemic therapy for treating HREC remains an area of active investigation. Adjuvant treatment of HREC is evolving, and patients should be individually treated with respect to the stage, histology, and prognostic factors.en_US
dc.identifier.doi10.5505/tjo.2017.1643en_US
dc.identifier.endpage132en_US
dc.identifier.issn1300-7467en_US
dc.identifier.issue3en_US
dc.identifier.pmid#YOKen_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage123en_US
dc.identifier.urihttps://dx.doi.org/10.5505/tjo.2017.1643
dc.identifier.urihttps://hdl.handle.net/20.500.12395/35448
dc.identifier.volume32en_US
dc.identifier.wosWOS:000424786500007en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherKARE PUBLen_US
dc.relation.ispartofTURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGYen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectChemotherapyen_US
dc.subjectendometrial canceren_US
dc.subjecthigh risken_US
dc.subjectradiotherapyen_US
dc.titleRole and Timing of Radiotherapy in High-Risk Endometrial Canceren_US
dc.typeReviewen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu